BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (NASDAQ:ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, announced today that it has completed enrollment for its pivotal U.S. clinical trial for MONOVISC™. The randomized, double-blind, controlled study is designed to demonstrate that the single-injection MONOVISC safely provides symptomatic relief of knee pain in patients with osteoarthritis. Anika enrolled approximately 350 patients at sites in the U.S. and Canada for the study, which includes a six-month follow-up period. The Company expects to commence commercialization in the United States in 2010.
